3-(4-氟苯基)哌啶盐酸盐 | 1106940-94-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-(4-氟苯基)哌啶盐酸盐
• 英文名称: 3-(4-fluorophenyl)piperidine hydrochloride
• 英文别名: 3-(4-fluorophenyl)piperidine;hydrochloride
• CAS: 1106940-94-6
• 化学式: C₁₁H₁₄FN*ClH
• 分子量: 215.698
• InChiKey: DGGGTQAVNWSYAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.71
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  3-(4-氟苯基)哌啶盐酸盐 、 (R)-2,3-dihydrobenzo[1,4]dioxine-2-carbonyl chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.83h， 生成 (R)-2,3-dihydrobenzo[1,4]dioxin-2-yl-((R)-3-(4-fluorophenyl)piperidin-1-yl)methanone 、 (R)-2,3-dihydrobenzo[1,4]dioxin-2-yl-((S)-3-(4-fluorophenyl)piperidin-1-yl)methanone
  参考文献：
  名称：

  [EN] 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES
  [FR] DÉRIVÉS DE 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMÉTHYLE UTILISÉS EN TANT QU'ANTAGONISTES DES ALPHA2C POUR TRAITER DES MALADIES DES SYSTÈMES NERVEUX PÉRIPHÉRIQUE ET CENTRAL

  摘要：

  式(I)的化合物，其中X、Z、R1-R4和m如权利要求中所定义，具有α2C拮抗活性，因此可用于治疗外周系统和中枢神经系统（CNS）的疾病和症状。

  公开号：

  WO2009013390A1

文献信息

• SULTAM DERIVATIVES
  申请人：Anderson Kevin W.

  公开号：US20110124686A1

  公开（公告）日：2011-05-26

  The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.

  本发明涉及符合式1的化合物，具有细胞毒活性。这些化合物可用于治疗癌症。
• [EN] SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS<br/>[FR] COMPOSÉS CARBAMATE SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU CANAL POTENTIEL RÉCEPTEUR TRANSITOIRE (TRP)
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014060341A1

  公开（公告）日：2014-04-24

  The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.

  该发明涉及式(I)的化合物及其药学上可接受的盐，其中Y、R1和R3在详细描述和权利要求中有定义。此外，本发明涉及制备和使用式(I)的化合物的方法，以及含有这些化合物的药物组合物。式(I)的化合物是TRPA1通道的拮抗剂，可能对治疗与该通道相关的炎症性疾病和紊乱有用。
• 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES
  申请人：Din Belle David

  公开号：US20120035210A9

  公开（公告）日：2012-02-09

  Compounds of formula I wherein X, Z, R 1 -R 4 , and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.

  式I的化合物，其中X、Z、R1-R4和m如权利要求所定义，表现出α2C拮抗活性，因此可用作α2C拮抗剂。还公开了治疗外周系统和中枢神经系统疾病和病症的方法。
• 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES
  申请人：ORION CORPORATION

  公开号：US20130281486A1

  公开（公告）日：2013-10-24

  Compounds of formula I wherein X, Z, R 1 -R 4 , and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.

  式(I)的化合物，其中X、Z、R1-R4和m如权利要求中所定义，表现出α2C拮抗活性，因此可用作α2C拮抗剂。还公开了治疗外周系统和中枢神经系统疾病和病况的方法。
• 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES
  申请人：ORION CORPORATION

  公开号：US20140179926A1

  公开（公告）日：2014-06-26

  Compounds of formula I wherein X, Z, R 1 -R 4 , and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.

  式I的化合物，其中X、Z、R1-R4和m的定义见权利要求，具有alpha2C拮抗活性，因此可用作alpha2C拮抗剂。本文还揭示了治疗外周系统和中枢神经系统疾病和病症的方法。